HARBIN, CHINA / ACCESSWIRE / April 4, 2016 / China Health Industries Holdings, Inc. (OTCQB: CHHE) (“China Health Industries” or “company”) today announced that the company has achieved a major technological breakthrough on its original product: Propolis and Black Ant Capsule.
China Health Industries owns proprietary intellectual property rights of Propolis and Black Ant Capsule (“the product”), which is designed to adjust human immunes system. It has been approved by China Food and Drug Administration (CFDA) put in production for years. The ingredients of the product — Propolis, Black Ant, Acanthopanax and Radix Astragali are originally from Heilongjiang Province, China. Located at 45 degrees north latitude area ensures that all the ingredients from Heilongjiang Province obtain high level of effective constituent. The traditional methods of extraction are not only wasteful of ingredients, but also show inability of extraction some of the component. Therefore, research groups of China Health Industries spend the last two years developing and finally made super-concentrated Propolis and Black Ant Capsule by technology of supercritical extraction and nanotechnology, with assist of using small molecule water.
CEO of China Health Industries, Mr. Xin Sun commented:” Healthcare is a competitive market, and the whole industry relies on escalation of technical and drug efficiency to move forward. Our new extraction technology and using of small molecule water could enhance the absorption of several enzymes from Propolis, amino acid and trace element from Black Ants, Isofraxidin and Astragaloside for human bodies, which essentially improve the efficacy of drug. ” Mr. Sun is very excited to say that “Our researchers conducted pharmacology and pharmacokinetics experiments, and the results show that the daily dosage of our new super-concentrated product could be reduced from three times a day, two capsules at a time to once and one capsule a day. The high absorbing efficiency of this super-concentrated product improved the bioavailability of it, thus improved the pharmacological efficacy. ” According to Mr. Sun’s estimation, the super-concentrated product will be put into the market by the second half of May, 2016. Mr. Sun believes that this new super-concentrated product will boost revenue of company.
China Health Industries Holdings, Inc. (www.chinahealth.tech) produces, markets and distributes high-quality medicines, health products, health devices and cosmetics. The Company routinely posts important information on its website.
CHHE owns GMP-certified plant and facilities and manufactures 21 CFDA-approved medicines and 14 CFDA-approved health supplement products in soft capsule, hard capsule, tablet, granule and oral liquid forms. These products address key major markets, including women’s products, geriatric products, children’s products and other vital market sectors.
Safe Harbor Statement
This press release contains certain statements that may include “forward-looking statements.” All statements other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on the SEC’s website (https://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Contact: Mr. Xin Sun Chairman & CEO
China Health Industries Holdings, Inc.